A Study of MK-2225 in Healthy Participants (MK-2225-003)

Last updated: March 25, 2025
Sponsor: Merck Sharp & Dohme LLC
Overall Status: Active - Recruiting

Phase

1

Condition

Collagen Vascular Diseases

Scleroderma

Connective Tissue Diseases

Treatment

Placebo

MK-2225

Clinical Study ID

NCT06643390
2225-003
MK-2225-003
  • Ages 18-55
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The purpose of the study is to learn about the safety of MK-2225, including how well people tolerate it. Researchers also want to learn what happens to different doses of MK-2225 in a person's body over time.

Eligibility Criteria

Inclusion

Inclusion Criteria:

The key inclusion criteria include but are not limited to the following:

  • Is in good health before randomization

  • Body Mass Index (BMI) ≤32 kg/m^2, inclusive

Exclusion

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

  • History of clinically significant endocrine, gastrointestinal (GI), cardiovascular,hematological, hepatic, immunological, renal, respiratory, genitourinary, or majorneurological (including stroke and chronic seizures) abnormalities or diseases

  • History of hypersensitivity to the MK-2225 drug substance, its inactive ingredientsor the placebo (normal saline)

Study Design

Total Participants: 32
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 1
Study Start date:
November 21, 2023
Estimated Completion Date:
October 25, 2025

Connect with a study center

  • Clinical Pharmacology of Miami (Site 0002)

    Miami, Florida 33014-3616
    United States

    Completed

  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO (Site 0004)

    Springfield, Missouri 65802
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.